1.
Early-life gut microbiome composition and milk allergy resolution
by Bunyavanich, Supinda, MD, MPH
Journal of allergy and clinical immunology, 2016, Vol.138 (4), p.1122-1130
2.
State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneous
by Jones, Stacie M., MD
Journal of allergy and clinical immunology, 2014, Vol.133 (2), p.318-323
3.
Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
by Jones, Stacie M., MD
Journal of allergy and clinical immunology, 2016, Vol.139 (4), p.1242-1252.e9
4.
Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
by Burks, A. Wesley, MD
Journal of allergy and clinical immunology, 2015, Vol.135 (5), p.1240-1248.e3
5.
ICON: Food allergy
by Burks, A. Wesley, MD
Journal of allergy and clinical immunology, 2012, Vol.129 (4), p.906-920
6.
A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response
by Varshney, Pooja, MD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.654-660
7.
The natural history of milk allergy in an observational cohort
by Wood, Robert A., MD
Journal of allergy and clinical immunology, 2012, Vol.131 (3), p.805-812.e4
8.
The natural history of egg allergy in an observational cohort
by Sicherer, Scott H., MD
Journal of allergy and clinical immunology, 2014, Vol.133 (2), p.492-499.e8
9.
Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy
by Brough, Helen A., MSc, FRCPCH
Journal of allergy and clinical immunology, 2014, Vol.135 (1), p.164-170.e4
10.
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial
by Fleischer, David M., MD
Journal of allergy and clinical immunology, 2012, Vol.131 (1), p.119-127.e7
11.
Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
by Jones, Stacie M., MD
Journal of allergy and clinical immunology, 2016, Vol.137 (4), p.1117-1127.e10
12.
Food allergy: A practice parameter update—2014
by Sampson, Hugh A., MD
Journal of allergy and clinical immunology, 2014, Vol.134 (5), p.1016-1025.e43
13.
Clinical efficacy and immune regulation with peanut oral immunotherapy
by Jones, Stacie M., MD
Journal of allergy and clinical immunology, 2009, Vol.124 (2), p.292-300.e97
14.
Mechanisms of immune tolerance relevant to food allergy
by Vickery, Brian P., MD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.576-584
15.
Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy
by Virkud, Yamini V., MD, MA, MPH
Journal of allergy and clinical immunology, 2016, Vol.139 (3), p.882-888.e5
16.
Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens
by Vickery, Brian P., MD
Journal of allergy and clinical immunology, 2012, Vol.131 (1), p.128-134.e3
17.
A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy
by Sampson, Hugh A., MD
Journal of allergy and clinical immunology, 2011, Vol.127 (5), p.1309-1310.e1
18.
Adverse reactions during peanut oral immunotherapy home dosing
by Varshney, Pooja, MD
Journal of allergy and clinical immunology, 2009, Vol.124 (6), p.1351-1352
19.
Oral tolerance, food allergy, and immunotherapy: Implications for future treatment
by Burks, A. Wesley, MD
Journal of allergy and clinical immunology, 2008, Vol.121 (6), p.1344-1350
20.
Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch
by Jones, Stacie M., MD
Journal of allergy and clinical immunology, 2016, Vol.137 (4), p.1258-1261.e10
